{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.","groups":[{"description":"Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and GCSF followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.","id":"OG000","title":"Recipient - Chemotherapy Group"},{"description":"3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m\\^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination","id":"OG001","title":"Donor - Vaccination Generation Group"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"9 years","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}